Glecaprevir and pibrentasvir and Rifadin IV

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using glecaprevir together with rifAMPin is not recommended. Combining these medications may significantly reduce the blood levels of both glecaprevir and pibrentasvir, the active components of your hepatitis C medication. This may make the medication less effective in treating your infection. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

CONTRAINDICATED: The plasma concentrations of glecaprevir may increase significantly during acute coadministration with rifampin, but decreases after chronic coadministration. Pibrentasvir plasma concentrations are not affected during acute coadministration with rifampin, but also decreases significantly after chronic coadministration. The proposed mechanism is rifampin inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake of glecaprevir initially, followed by induction of P-glycoprotein-mediated intestinal efflux and CYP450 3A4-mediated metabolism of glecaprevir and pibrentasvir after chronic dosing. In 12 study subjects, glecaprevir peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 6.5- and 8.6-fold, respectively, after a single 300 mg-120 mg dose of glecaprevir-pibrentasvir was administered with the first 600 mg dose of rifampin. Following multiple dosing of rifampin 600 mg once daily, however, glecaprevir Cmax and AUC decreased by 86% and 88%, respectively, while pibrentasvir Cmax and AUC decreased by 83% and 87%, respectively. High plasma levels of glecaprevir may increase the risk of adverse effects such as alanine aminotransferase (ALT) and bilirubin elevations, whereas low plasma levels of glecaprevir and pibrentasvir may reduce viral susceptibility and increase the risk of resistance development.

MANAGEMENT: Concomitant use of glecaprevir and pibrentasvir with rifampin is considered contraindicated.

Glecaprevir and pibrentasvir

Generic Name: glecaprevir / pibrentasvir

Brand name: Mavyret

Synonyms: Glecaprevir and Pibrentasvir

What is Glecaprevir and pibrentasvir?

Rifadin IV

Generic Name: rifampin

Brand name: Rifadin IV, Rifadin, Rimactane

Synonyms: n.a.

What is Rifadin IV?